Comparative boxplots of effective reproduction number (<i>R</i>_<i>t</i>) similarity distributions in synthetic SIRDS outbreaks. by Hélder Seixas Lima (18840636)

SIRDS model simulations across three years for different basic reproduction numbers (<i>R</i>₀). by Hélder Seixas Lima (18840636)

Longitudinal YU2 gp120 WT-reactive CD4i IgG binding antibodies elicited in RV144 and RV305 (related to Fig 1). by LaTonya D. Williams (3140490)

Loss of <i>A</i>-homeostasis in the m7 controller with a random-order ternary-complex mechanism (Fig 51) when <i>k</i>₆ > <i>k</i>₅. by Qaiser Waheed (5095328)

“…(c) Decrease of <i>A</i> as a function of time when <i>k</i>₆=40.0. …”

A significant interaction of FC among cerebellar sub-regions and cerebral cortexes. by Mengling Shao (7450343)

“…The experimental group had stronger FC between left cerebellar hemispheric IV-V (A) and right cerebellar hemispheric VIII (B); between right cerebellar hemispheric VIII (B) and right hippocampus (C); between right cerebellar hemispheric VIII (B) and left middle cingulate gyrus (D); between cerebellar vermal IX (E) and right cerebellar hemispheric VIII (B) after training. …”

Bayesian evolutionary analysis of DENV-2 isolated from one patient in 2016 in Tainan, Taiwan. by You-Yuan Tsai (3142086)

Illustration of the Susceptible-Infected-Recovered-Dead-Susceptible (SIRDS) model. by Hélder Seixas Lima (18840636)

Time-varying model parameters fitted for Covid-19 in Brazil. by Hélder Seixas Lima (18840636)

DataSheet1_A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center,... by Anju Majeed (19169428)

“…</p>Methods<p>Based on the inclusion/exclusion criteria, 105 newly diagnosed participants with degenerative hypertrophy OA were recruited and randomized into Placebo, BSE-150 mg or BSE-300 mg (n = 35 in each group) to receive either 150 mg or 300 mg BSE or a placebo tablet twice a day for 90 days. All the participants were evaluated for pain and physical function using the standard tools including the Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne Functional Index (LFI), EuroQol- 5 Dimension (EQ-5D) quality of life, 6-min walk test at day 0, days 5, 30, 60 and 90 of treatment. …”

Boxplots illustrating key metrics of the model optimization process for infection periods ranging from 8 to 20 days. by Hélder Seixas Lima (18840636)

Comprehensive analysis of simulation results for Covid-19 in Brazil. by Hélder Seixas Lima (18840636)

IGF1 has no effect on SGHPL-5 cell invasiveness. by Allerdien Visser (1805944)

“…Inhibiting PI3K by adding LY294002 decreases invasion of SGHPL-5 cells significantly. …”

Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 response magnitudes at RV144 week 26 versus RV305 week 2 and RV305 week 2 versus RV305 week... by LaTonya D. Williams (3140490)

Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG4 response magnitudes at RV144 week 26 versus RV305 week 2 and RV305 week 2 versus RV305 week... by LaTonya D. Williams (3140490)

Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG breadth scores at RV144 week 26 and RV305 week 2 (primary analysis) and RV14... by LaTonya D. Williams (3140490)

Quantitative real-time PCR analysis of Type I fimbrial gene expression in Δ<i>ecf5</i> and Δ<i>ecf7</i> mutants of B728a. by Poulami Basu Thakur (389600)

“…Negative values indicate a decrease in expression levels as computed by taking the negative inverse of a fold change value less than 1.…”

Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) total IgG and IgG1 response magnitudes at RV144 week 26 versus RV305 week 2, RV3... by LaTonya D. Williams (3140490)

Durability of IgG3 responses. by LaTonya D. Williams (3140490)

Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and A... by LaTonya D. Williams (3140490)

Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG4 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and A... by LaTonya D. Williams (3140490)